Oncology prescribing has changed with the broad adoption of clinical pathways programs, bundled payment arrangements, and accountable care organizations (ACOs). Each of these managed care reforms is designed to promote cost-effective and evidence-based prescribing while working to lower costs of care, but each mechanism works differently to benefit or hamper specific oncology brands.<\/p>\n
This report explores how these three managed care forces are reshaping the competitive pharmaceutical landscape for drugs treating colorectal cancer (CRC) and renal cell carcinoma (RCC) in different ways.<\/p>\n
The landscape of agents for the treatment of CRC and RCC is changing, owing to the 2013 approval of capecitabine, the generic version of Roche\u2019s oral Xeloda. The introduction of the generic version may attract oncologists to try it as single-agent therapy in stage III and IV CRC, potentially supplanting chemotherapy and chemotherapy with targeted agents (a crowded field including FOLFOX, CAPOX, and 5-FU\/leucovorin in stage III, and Roche\/Chugai\u2019s Avastin (bevacisumab), Bristol-Myers Squibb\/Eli Lilly\/Merck\/Serono\u2019s Erbitux (cetuximab), Regeneron\/Sanofi\u2019s Zaltrap (ziv-aflibercept), and Amgen\/Takeda\u2019s Vectibix (panitumumab) in stage IV). The CRC market is poised for further change with the forecast 2016 launch of OncoVax, an immunotherapy for use as first-line therapy after surgery in stage II. To the extent that this agent succeeds in preventing recurrence, it will inhibit sales of all other agents for CRC.<\/p>\n
In the RCC and CRC markets, prescribers\u2019 choice of therapy and payers\u2019 decisions about formulary inclusion and pathway placement will become increasingly complex as developers strive to differentiate new entrants within the evolving treatment algorithms and to position themselves as favorably as possible on payers\u2019 formularies and on pathways.<\/p>\n
In this report, we surveyed 100 oncologists and 40 managed care organization (MCO) pharmacy and medical directors to assess their attitudes, expectations, and reservations regarding pathways, bundled payment arrangements, and ACOs. We then pressed for detailed responses about how these managed care reforms are likely to influence access to, and prescribing of, specific agents.<\/p>\n","protected":false},"template":"","class_list":["post-391729","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-colorectal-cancer","biopharma-therapy-areas-oncology","biopharma-therapy-areas-renal-cell-carcinoma","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391729\/revisions"}],"predecessor-version":[{"id":577046,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391729\/revisions\/577046"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}